Review





Similar Products

93
Bio X Cell anti fcγr antibody
Anti Fcγr Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fc%CE%B3r/InVivoMAb+anti-mouse+CD16%2E2/bio_rxiv__64898__2026__10__12__756217-214-6-10
Average 93 stars, based on 1 article reviews
anti fcγr antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Sino Biological recombinant biotinylated fcγr proteins
Recombinant Biotinylated Fcγr Proteins, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fc%CE%B3r/Human+CD16a+%2F+FCGR3A+Protein+(176+Phe%2C+His+%26+AVI+Tag)%2C+Biotinylated/pmc13627347-79-0-4
Average 94 stars, based on 1 article reviews
recombinant biotinylated fcγr proteins - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
Cell Signaling Technology Inc anti mouse fcγr
Anti Mouse Fcγr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fc%CE%B3r/CD64%2FFcgammaRI+Rabbit+mAb/pm41764720-72-59-63
Average 92 stars, based on 1 article reviews
anti mouse fcγr - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

96
ATCC fcγr murine mastocytoma cell line p815
Fcγr Murine Mastocytoma Cell Line P815, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fc%CE%B3r/P815/bio_rxiv__64898__2026__04__13__718113-101-6-13
Average 96 stars, based on 1 article reviews
fcγr murine mastocytoma cell line p815 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

99
Agilent technologies fcγr binding pe streptavidin
A) Heatmap of <t>FcγR-binding</t> antibody responses to SARS-CoV-2 S antigens in mild and severe COVID-19 patients. Binding activity of antibodies to FcγRs was measured for SARS-CoV-2 full-length S, S1 and S2 antigens at days 0, 3, 7, and 46 post-recruitment. Box-and-whisker diagrams showing (B) FcγR2AH and FcγR2AR-binding antibody responses (C) FcγR3AV and FcγR3AF-binding titers, (D) functional monocyte antibody-dependent cellular phagocytosis (ADCP) responses and (E) functional antibody-dependent neutrophil phagocytosis (ADNP) responses against SARS-CoV-2 full-length S, S1 and S2 antigens in mild and severe COVID-19 patients. Box indicates interquartile range (IQR, Q1-Q3), with horizontal line showing the median and vertical lines indicating minimum and maximum. Mann-Whitney U test was performed to compare differences between mild vs. severe patients at each time point. Statistical significance was considered when p ≤ 0.05. F) PCA of antibody responses according to day of recruitment (day 0: blue; day 3: red; day 7: green and day 46: purple). Empty circles represent mild cases, and filled circles represent severe cases. Ellipses show 95% confidence regions. G) Spider plot of the antibody landscape (IgG antibody titers, FcγR-binding activity and FcγR-effector functions) in mild and severe COVID-19 patients. Median percentile for each antibody feature is shown at each timepoint and for each SARS-CoV-2 S antigen.
Fcγr Binding Pe Streptavidin, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fc%CE%B3r/Streptavidin/med_rxiv__64898__2026__02__18__26346542-312-4-7
Average 99 stars, based on 1 article reviews
fcγr binding pe streptavidin - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

86
Biacore fcγrs
A) Heatmap of <t>FcγR-binding</t> antibody responses to SARS-CoV-2 S antigens in mild and severe COVID-19 patients. Binding activity of antibodies to FcγRs was measured for SARS-CoV-2 full-length S, S1 and S2 antigens at days 0, 3, 7, and 46 post-recruitment. Box-and-whisker diagrams showing (B) FcγR2AH and FcγR2AR-binding antibody responses (C) FcγR3AV and FcγR3AF-binding titers, (D) functional monocyte antibody-dependent cellular phagocytosis (ADCP) responses and (E) functional antibody-dependent neutrophil phagocytosis (ADNP) responses against SARS-CoV-2 full-length S, S1 and S2 antigens in mild and severe COVID-19 patients. Box indicates interquartile range (IQR, Q1-Q3), with horizontal line showing the median and vertical lines indicating minimum and maximum. Mann-Whitney U test was performed to compare differences between mild vs. severe patients at each time point. Statistical significance was considered when p ≤ 0.05. F) PCA of antibody responses according to day of recruitment (day 0: blue; day 3: red; day 7: green and day 46: purple). Empty circles represent mild cases, and filled circles represent severe cases. Ellipses show 95% confidence regions. G) Spider plot of the antibody landscape (IgG antibody titers, FcγR-binding activity and FcγR-effector functions) in mild and severe COVID-19 patients. Median percentile for each antibody feature is shown at each timepoint and for each SARS-CoV-2 S antigen.
Fcγrs, supplied by Biacore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fc%CE%B3r/anti+fc%CE%B3rs/us12509518-1666-14-18
Average 86 stars, based on 1 article reviews
fcγrs - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Routledge Ltd fcγr
A) Heatmap of <t>FcγR-binding</t> antibody responses to SARS-CoV-2 S antigens in mild and severe COVID-19 patients. Binding activity of antibodies to FcγRs was measured for SARS-CoV-2 full-length S, S1 and S2 antigens at days 0, 3, 7, and 46 post-recruitment. Box-and-whisker diagrams showing (B) FcγR2AH and FcγR2AR-binding antibody responses (C) FcγR3AV and FcγR3AF-binding titers, (D) functional monocyte antibody-dependent cellular phagocytosis (ADCP) responses and (E) functional antibody-dependent neutrophil phagocytosis (ADNP) responses against SARS-CoV-2 full-length S, S1 and S2 antigens in mild and severe COVID-19 patients. Box indicates interquartile range (IQR, Q1-Q3), with horizontal line showing the median and vertical lines indicating minimum and maximum. Mann-Whitney U test was performed to compare differences between mild vs. severe patients at each time point. Statistical significance was considered when p ≤ 0.05. F) PCA of antibody responses according to day of recruitment (day 0: blue; day 3: red; day 7: green and day 46: purple). Empty circles represent mild cases, and filled circles represent severe cases. Ellipses show 95% confidence regions. G) Spider plot of the antibody landscape (IgG antibody titers, FcγR-binding activity and FcγR-effector functions) in mild and severe COVID-19 patients. Median percentile for each antibody feature is shown at each timepoint and for each SARS-CoV-2 S antigen.
Fcγr, supplied by Routledge Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fc%CE%B3r/anti+fc%CE%B3r/us12486321-206-15-39
Average 86 stars, based on 1 article reviews
fcγr - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Merck & Co fcγr
A) Heatmap of <t>FcγR-binding</t> antibody responses to SARS-CoV-2 S antigens in mild and severe COVID-19 patients. Binding activity of antibodies to FcγRs was measured for SARS-CoV-2 full-length S, S1 and S2 antigens at days 0, 3, 7, and 46 post-recruitment. Box-and-whisker diagrams showing (B) FcγR2AH and FcγR2AR-binding antibody responses (C) FcγR3AV and FcγR3AF-binding titers, (D) functional monocyte antibody-dependent cellular phagocytosis (ADCP) responses and (E) functional antibody-dependent neutrophil phagocytosis (ADNP) responses against SARS-CoV-2 full-length S, S1 and S2 antigens in mild and severe COVID-19 patients. Box indicates interquartile range (IQR, Q1-Q3), with horizontal line showing the median and vertical lines indicating minimum and maximum. Mann-Whitney U test was performed to compare differences between mild vs. severe patients at each time point. Statistical significance was considered when p ≤ 0.05. F) PCA of antibody responses according to day of recruitment (day 0: blue; day 3: red; day 7: green and day 46: purple). Empty circles represent mild cases, and filled circles represent severe cases. Ellipses show 95% confidence regions. G) Spider plot of the antibody landscape (IgG antibody titers, FcγR-binding activity and FcγR-effector functions) in mild and severe COVID-19 patients. Median percentile for each antibody feature is shown at each timepoint and for each SARS-CoV-2 S antigen.
Fcγr, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fc%CE%B3r/fc%CE%B3r/us12428481-490-30-58
Average 86 stars, based on 1 article reviews
fcγr - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc antibodies fc gamma receptor fcγr iib
A) Heatmap of <t>FcγR-binding</t> antibody responses to SARS-CoV-2 S antigens in mild and severe COVID-19 patients. Binding activity of antibodies to FcγRs was measured for SARS-CoV-2 full-length S, S1 and S2 antigens at days 0, 3, 7, and 46 post-recruitment. Box-and-whisker diagrams showing (B) FcγR2AH and FcγR2AR-binding antibody responses (C) FcγR3AV and FcγR3AF-binding titers, (D) functional monocyte antibody-dependent cellular phagocytosis (ADCP) responses and (E) functional antibody-dependent neutrophil phagocytosis (ADNP) responses against SARS-CoV-2 full-length S, S1 and S2 antigens in mild and severe COVID-19 patients. Box indicates interquartile range (IQR, Q1-Q3), with horizontal line showing the median and vertical lines indicating minimum and maximum. Mann-Whitney U test was performed to compare differences between mild vs. severe patients at each time point. Statistical significance was considered when p ≤ 0.05. F) PCA of antibody responses according to day of recruitment (day 0: blue; day 3: red; day 7: green and day 46: purple). Empty circles represent mild cases, and filled circles represent severe cases. Ellipses show 95% confidence regions. G) Spider plot of the antibody landscape (IgG antibody titers, FcγR-binding activity and FcγR-effector functions) in mild and severe COVID-19 patients. Median percentile for each antibody feature is shown at each timepoint and for each SARS-CoV-2 S antigen.
Antibodies Fc Gamma Receptor Fcγr Iib, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fc%CE%B3r/pm40845407-107-43-48
Average 86 stars, based on 1 article reviews
antibodies fc gamma receptor fcγr iib - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


A) Heatmap of FcγR-binding antibody responses to SARS-CoV-2 S antigens in mild and severe COVID-19 patients. Binding activity of antibodies to FcγRs was measured for SARS-CoV-2 full-length S, S1 and S2 antigens at days 0, 3, 7, and 46 post-recruitment. Box-and-whisker diagrams showing (B) FcγR2AH and FcγR2AR-binding antibody responses (C) FcγR3AV and FcγR3AF-binding titers, (D) functional monocyte antibody-dependent cellular phagocytosis (ADCP) responses and (E) functional antibody-dependent neutrophil phagocytosis (ADNP) responses against SARS-CoV-2 full-length S, S1 and S2 antigens in mild and severe COVID-19 patients. Box indicates interquartile range (IQR, Q1-Q3), with horizontal line showing the median and vertical lines indicating minimum and maximum. Mann-Whitney U test was performed to compare differences between mild vs. severe patients at each time point. Statistical significance was considered when p ≤ 0.05. F) PCA of antibody responses according to day of recruitment (day 0: blue; day 3: red; day 7: green and day 46: purple). Empty circles represent mild cases, and filled circles represent severe cases. Ellipses show 95% confidence regions. G) Spider plot of the antibody landscape (IgG antibody titers, FcγR-binding activity and FcγR-effector functions) in mild and severe COVID-19 patients. Median percentile for each antibody feature is shown at each timepoint and for each SARS-CoV-2 S antigen.

Journal: medRxiv

Article Title: Early Fc-effector antibody signatures impact COVID-19 disease trajectory

doi: 10.64898/2026.02.18.26346542

Figure Lengend Snippet: A) Heatmap of FcγR-binding antibody responses to SARS-CoV-2 S antigens in mild and severe COVID-19 patients. Binding activity of antibodies to FcγRs was measured for SARS-CoV-2 full-length S, S1 and S2 antigens at days 0, 3, 7, and 46 post-recruitment. Box-and-whisker diagrams showing (B) FcγR2AH and FcγR2AR-binding antibody responses (C) FcγR3AV and FcγR3AF-binding titers, (D) functional monocyte antibody-dependent cellular phagocytosis (ADCP) responses and (E) functional antibody-dependent neutrophil phagocytosis (ADNP) responses against SARS-CoV-2 full-length S, S1 and S2 antigens in mild and severe COVID-19 patients. Box indicates interquartile range (IQR, Q1-Q3), with horizontal line showing the median and vertical lines indicating minimum and maximum. Mann-Whitney U test was performed to compare differences between mild vs. severe patients at each time point. Statistical significance was considered when p ≤ 0.05. F) PCA of antibody responses according to day of recruitment (day 0: blue; day 3: red; day 7: green and day 46: purple). Empty circles represent mild cases, and filled circles represent severe cases. Ellipses show 95% confidence regions. G) Spider plot of the antibody landscape (IgG antibody titers, FcγR-binding activity and FcγR-effector functions) in mild and severe COVID-19 patients. Median percentile for each antibody feature is shown at each timepoint and for each SARS-CoV-2 S antigen.

Article Snippet: For the analysis of FcγR binding PE-Streptavidin (Agilent Technologies, CA, USA) was coupled to recombinant and biotinylated human FcγR2AH/R, FcγR2B, FcγR3AF/R and FcγR3B (Duke Human Vaccine Institute Protein Production Facility).

Techniques: Binding Assay, Activity Assay, Whisker Assay, Functional Assay, MANN-WHITNEY